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Summary
Solvent facilitated perfusion (SFP) has been proposed as a technique to increase the delivery of chemotherapeutic
agents to tumors. SFP entails direct injection of the agent into the tumor in a water-miscible organic solvent, and
because the solvent moves easily through both aqueous solutions and cellular membranes it drives the penetration of
the solubilized anticancer agent throughout the tumor. To test this hypothesis, we compared the pharmacokinetics
(PK) of 14C-labeled 1,3-bis-chlorethyl-1-nitrosourea (BCNU) in intra-cerebral 9L rat gliomas after intravenous (IV)
infusion in 90% saline –10% ethanol or direct intratumoral (IT) injection of 14C-BCNU in 100% ethanol (DTI-015).
TreatmentwithDTI-015 yielded a peak radioactive count (Cmax) for the 14C label that was 100–1000 fold higher in the
tumor than in all other tissues in addition to a concentration in the tumor that was 100-fold higher than that achieved
following IV infusion of 14C-BCNU. Pathologic and auto-radiographic analysis of tissue sections following IT
injection of 14C-BCNU in ethanol into either tumor or normal rat brain revealed both an enhanced local volume of
distribution and an increased concentration of BCNU delivered to tumor compared to non-tumor bearing brain. To
investigate the mechanism behind the SFP of BCNU to the tumor both dynamic contrast and perfusion MRI were
performed on 9L tumors before and after treatment and demonstrated a decrease in tumor perfusion following IT
injection of DTI-015. Finally, initial PK of patient blood samples following administration of DTI-015 into relapsed
high-grade glioma indicated a 20-fold decrease in systemic exposure to BCNU compared to IV infusion of BCNU
providing further evidence for the enhanced therapeutic ratio observed for DTI-015.
Abbreviations: AUC – area under the concentration–time curve; BCNU – 1,3-bis-chlorethyl-1-nitrosourea; CED –
convection enhanced delivery; Cmax – peak concentration; CPM – counts per minute; DTI-015 – BCNU prepared
in 100% ethanol; IT – intratumoral; IV – intravenous; LD10 – the dose of drug which results in death of 10% of the
animals due to drug toxicity; MRI – magnetic resonance imaging; PK – pharmacokinetics; SEM – standard error of
the mean; SFP – solvent facilitated perfusion; t1/2 – half-life; TTR – tumor-to-tissue ratio
Introduction
High-grade malignant glioma carries a grave prognosis
with median survival typically less than 12 months from
diagnosis even with aggressive treatment. The typical
management strategy entails maximal surgical resection
followed by post-operative radiotherapy [1]. Intrave-
nously administered BCNU has been the leading che-
motherapeutic agent for treating this patient population
for decades; however, despite activity against glioma
cells both in culture and in animal models there is lim-
ited clinical efficacy which has prompted numerous
investigations into ways to enhance the pharmacoki-
netics (PK) of this agent [2]. The limited efficacy of
adjuvant chemotherapy for high-grade gliomas was
highlighted in a recent meta-analysis which indicated
only a 6% increase in median survival in patients treated
with adjuvant chemotherapy (typically BCNU) follow-
ing maximal surgical resection and ⁄ or radiation therapy
[3].
Attempts to increase this response through dose
escalation of BCNU administered systemically have
been hampered by acute toxicity to bone marrow and
gastrointestinal tract and delayed toxicity to liver and
lungs [2,4–6]. Therefore, local ⁄ regional delivery of
BCNU either through intra-arterial infusion [7,8] or
through the use of BCNU impregnated wafers
implanted in the resection cavity (Gliadel) have been
attempted [9,10]. Unfortunately, neither of these tech-
niques has offered a significant advantage over tradi-
tional IV infusion of BCNU. Intra-arterial infusion
resulted in a less than 4-fold increase in tumor-to-tissue
ratio (TTR) and was complicated by unacceptable optic
and neurologic toxicity [11,12]. Following the difficulty
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with local intra-arterial delivery attempts were made
using BCNU contained within a sustained release for-
mulation implanted directly into the resection cavity.
Initial studies utilized relatively low dose wafers which
gave only a modest increase in survival following
treatment of recurrent or primary glioblastoma [10,13].
More recent studies have evaluated wafers containing
increased concentrations of BCNU, but these eventually
produced both local and systemic toxicity and the clin-
ical benefit of these higher dose wafers has yet to be
demonstrated [14]. In part, this limited efficacy may be
due to the fact that Gliadel wafers are limited by bulk
diffusion of BCNU from the implant to surrounding
tissues, and are, therefore, only utilizable after maximal
surgical resection and even then there is still limited
entrance of drug into the surrounding tissues, which is
typically not more than a few millimeters [15]. Due to
the limited transit of drug direct intratumoral infusion
of drugs in aqueous solutions (convection enhanced
delivery, CED) has been investigated to increase delivery
to the tumor while also enhancing the TTR [16]. How-
ever, this technique is limited by the long time required
for infusion and by limited and heterogeneous distri-
bution of the compounds within the tumor [17]. Despite
this fact CED is being actively pursued both in pre-
clinical models [18] and in clinical investigation for pa-
tients with high-grade glioma [19].
Solvent facilitated perfusion (SFP) is another new
treatment technique which has been proposed to achieve
an enhanced TTR for chemotherapeutic agents. This
method utilizes a water-miscible organic solvent that can
move freely though both aqueous solutions and cell
membranes thus facilitating transit of the chemothera-
peutic agent some distance from the tumor. BCNU
suspended in 100% ethanol (herein termed DTI-015) is
the first drug : solvent system to be used to study this
SFP model. It has been evaluated both in animal models
and in patients with recurrent high-grade glioma and in
both cases DTI-015 was demonstrated to have signifi-
cant anti-tumor activity [20,21]. In one preclinical
model, treatment of rats bearing T9 gliosarcomas with
DTI-015 resulted in a >400% increase in life-span with
40% of animals cured of their tumors [21]. In a separate
study, diffusion-weighted MRI was performed following
the injection of DTI-015 into established 9L gliosarco-
mas and revealed a rapid and substantial increase in the
apparent diffusion coefficient (ADC), which is a radio-
logic measure of cell death [22], followed by significant
regression of the tumor mass with 75% of animals free
of tumor by MRI and pathologic analysis at 30 days
[23]. More importantly, changes in ADC were witnessed
throughout the tumor despite the fact that the volume of
DTI-015 injected was at most 50% of the tumor volume.
These diffuse changes in ADC throughout the injected
tumors were thus an indirect suggestion of SFP of drug
to the entire tumor mass. Finally, a recent phase I ⁄ II
trial was reported on 40 heavily pretreated patients with
inoperable recurrences of primary brain tumors (90% of
which were WHO grade III or IV), 58% of whom had
been previously treated with nitrosoureas. Despite this
previously treated population there was a significant
benefit in patients treated with less than or equal to the
maximal tolerated dose of DTI-015 (240 mg and 5 ml)
where the median survival was 55 weeks in patients with
recurrent, inoperable GBM, as compared to a historical
control of 25 weeks [20].
Despite these preclinical and clinical data the local
and systemic PK of BCNU following injection of DTI-
015 into intra-cerebral tumors in either experimental
animals or clinical samples has not been reported. We,
therefore, evaluated the distribution of radioactivity
following IT or IV injection of 14C-BCNU in Fischer
344 rats bearing established 9L gliosarcomas, and uti-
lized MRI measures of tumor perfusion to more fully
evaluate the PK of DTI-015 administration. Finally, the
initial pilot experience with the systemic PK of BCNU
following IT treatment with DTI-015 in patients with
recurrent gliomas is reported.
Materials and methods
Cell culture
Rat 9L brain tumor cells (passage 12) were obtained
from the Brain Tumor Research Center at the Univer-
sity of California at San Francisco. The cells were grown
as monolayers in 175 cm2 sterile plastic flasks in Eagle’s
MEM with 10% fetal bovine serum. Cells were cultured
at 37 C in an atmosphere containing 95 ⁄ 5% air ⁄CO2
until confluent, and were harvested by trypsinization,
counted, and resuspended in serum-free medium for
injection. The 9L cells were carried only until passage
number 40 at which time cells were reactivated from
frozen stocks.
Animals
Male Fischer 344 (F344/NHsd) rats were obtained from
Harlan Sprague Dawley (Indianapolis, IN) and were
acclimated in house, 2 per cage with food and water
ad libitum for at least 1 week prior to experimentation.
Animals weighing 125–150 were used for tumor cell
implantation and subsequent treatment with DTI-015 or




activity 53 mCi/mol) or 1,3-bis(2-chlorethyl-[2-14C])-
1-nitrosourea (specific activity 205 mCi ⁄mol) were
obtained from Moravek Biochemicals Inc (Brea, CA) as
a dry solid packaged under argon. The materials were
reconstituted in ethanol containing unlabeled BCNU at
a concentration of 67 mg ⁄ml to give the DTI-015
formulation.
For experiments evaluating the distribution of 14C
labeled BCNU within tumor or normal brain slices the
compound with 14C in the carbonyl position was utilized
where a total of 15 ll of DTI-015 was injected con-
taining 1 mg of unlabeled BCNU and 135 nCi. In all
other PK experiments, the compound with 14C in the
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ethyl position was utilized with a total of 15 ll of DTI-
015 injected containing 1 mg of unlabeled BCNU and
1 lCi. For intravenous administration the 1,3-bis(2-
chlorethyl-[2-14C])-1-nitrosourea compound was recon-
stituted in ethanol containing unlabeled BCNU and
further diluted in saline to a concentration of 1 mg
BCNU (containing 1 lCi) per 900 ll ethanol/saline
(10%/90%).
Induction of brain tumors
Intra-cerebral tumor implantation was performed as
previously described (24). Male Fischer 344 rats weigh-
ing between 125 and 150 g were anesthetized with a
ketamine ⁄ xylazine mixture administered intraperitone-
ally. A small skin incision was made over the right
hemisphere, and a 1 cm diameter burr hole was drilled
through the skull using a high speed drill. Tumor cells
(105) contained in a volume of 5 ll were injected into the
right forebrain at a depth of 3 mm via a Hamilton
syringe equipped with a 30 gauge needle. The area was
rinsed with 70% ethanol, and the burr hole was filled
with bone wax to minimize extra-cerebral extension of
the tumor. The skin incision was closed with sutures,
and the rats were allowed to recover from anesthesia
before being returned to the animal quarters.
Magnetic resonance imaging
All in vivo MR experiments were performed on a Varian
NMR Instruments system equipped with a 7.0 T
(300 MHz proton frequency), 18.3-cm horizontal bore
magnet. For MRI examination rats were anesthetized
with 1.5% isoflurane and maintained at 37 C inside the
magnet using a heated circulating water blanket. MRI of
rat brains were initiated between 8 and 11 days after cell
implantation and repeated approximately every 2 days
using a 32-mm-diameter quadrature radio frequency
head coil (USA Instruments, Highland Heights, OH).
Multislice axial T2 weighted images (FOV ¼ 30 · 30 mm
and image matrix ¼ 128 · 128) were acquired by using a
fastspin echo (FSE) sequence (TR/TEeff ¼ 4000 ⁄ 45 ms,
ETL ¼ 8, Thk ¼ 1 mm). The tumor boundary visualized
in each slice was electronically outlined by using image
processing software (MATLAB) for calculation of
tumor volume. For quantification of contrast agent
uptake T1 weighted spin echo MRI was performed
pre- and post intra-peritoneal injection of GdDTPA
(1.0 ml of 20% Magnevist). TR ⁄TE ¼ 1000 ⁄ 15 ms,
thk =1 mm, FOV ¼ 30 · 30 mm and image matrix ¼
128 · 128. For blood flow imaging, continuous arterial
spin labeling (CASL) MRI was performed with a FSE
based imaging sequence. Briefly a 3 second train of
hyperbolic inversion pulses was used to invert the signal
arising from inflowing blood, immediately before the
initial 90o pulse of a 16-echo, 128-phase FSE sequence
(TR ⁄TEeff of 4000 ⁄ 14 ms, 2 mm slice thickness and 8
transients). The images were acquired with a field 3 · 3
cm field of view and the 128 · 128 acquisition matrix was
subsequently zero-filled to 256 · 256. A T1 map of the
imaged slice was also acquired with a magnetization
inversion-prepared 16-echo, 64-phase encoding FSE
sequence. Five different inversion times, Ti, were used
with 2 transients and TR ⁄TEeff of 10,000 ⁄ 14 ms. Perfu-
sion images or TBF maps were calculated using the






where k is the blood/tissue partition function (assumed
to be 0.9), T1 is the tissue longitudinal relaxation time,
S0 and S1 are the image signals with inversion pulses
applied to control and tag zones respectively, and a is
the efficiency of the inversion pulses. All MRI acquisi-
tion matrices were zero filled to 256 · 256 so that the
resulting image dimensions were identical.
Stereotactic injections of DTI-015
When tumors had reached a mean volume of
65 ± 7.5 ll rats were anesthetized with 0.1–0.2 ml
ketamine HCl (100 mg ⁄ml) intramuscularly and placed
in the stereotactic device (David Kopf Instruments,
Tujunga, CA) with the bite bar set at )2.4 mm. The
scalp was opened with a scalpel and the skull was
cleaned of tissue to locate the original burr hole made
for tumor cell injection. The injection needle made
from 30 gauge stainless steel tubing (HTX-30, Small
Parts Inc, Miami Lakes, FL) attached to PE-10 poly-
ethylene tubing (Clay Adams, Parsippany, NJ) was
placed in the hole just touching the surface of the brain
and the scale was read. From this point the needle was
introduced into the tumor a distance approximately the
total depth of the tumor and then retracted to the
midpoint of the tumor (as determined by diagrams of
MR images obtained 2 days previously). Using a
Harvard Pump 11 and a 50 ll Hamilton syringe, 15 ll
of [14C]-BCNU was infused over 2 m in at a rate of
7.5 ll ⁄min. The needle was left in place an additional
30 s to promote diffusion of the injection into the
tumor and to prevent the drawing of [14C]-BCNU
along the needle track upon withdrawal. For injections
into normal brains of non-tumor bearing animals,
injections were made 3 mm below the dura.
Animal termination
Representative animals from each group were killed by
decapitation at the indicated times post injection and the
brains were quickly removed. For experiments requiring
sectioning they were immediately mounted in anticipa-
tion of coronal tissue sectioning (see below). In separate
experiments for kinetic data analysis a blood sample was
obtained prior to euthanasia. Once the animal had been
harvested the brains were removed and the tumors
teased out in its entirety and transferred to an appro-
priate vial. Small slabs of ipsilateral (adjacent to the
tumor) and contralateral cortex were subsequently ta-
ken. An incision was made in the abdomen past the
sternum and small samples of the following tissues were
taken (in the following order): lung, liver, kidney (left),
spleen, bone marrow (right femur), and testis (left).
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Frozen sections
Upon sacrifice, the forebrain was cut from the hindbrain
and mounted on a small piece of gauze saturated with
M-1 embedding medium (Shandon-Lipshaw, Pittsburg,
PA) on a glass slide oriented for coronal sectioning. This
was then frozen with crushed dry ice and coated withM-1
before storing at )80 C. The tissue gauze was thawed
from the slide and mounted on a chuck with additional
M-1 and surrounded by crushed dry ice to freeze the
media. The tissue was then placed in the cryostat (Hacker
Instruments, Fairfield, NJ) and allowed to equilibrate to
chamber temperature before sectioning. Serial sections
through the tumor were collected beginning prior to the
tumor and ending just after the tumor disappeared from
the tissue. Serial 20 lm sections were cut, placed on slides
(three sections per slide), and high temperature thaw
mounted to prevent diffusion of the label and completely
dry the sections. Slides were placed in X0ray cassettes
with radioactive standards and opposed to Hyperfil
b-max (Amersham, Arlington Heights, IL) for 6 days.
Films were developed in D-19 (Kodak, Rochester, NY)
for 4 min, transferred to 1% acetic acid stop bath for 30 s
and fixed with Rapid Fixer (Kodak) for 5 min. The films
were washed in running tap water for 20 min, rinsed in
distilled water, and air dried.
Brain radiolabel densitometry
Auto radiograms were analyzed using imaging software
(Imaging Research Inc, St. Catherines, Ontario, Can-
ada). Scanning coordinates on selected slides were
arbitrarily chosen to be representative and the autora-
diographs were scanned with s Sony XC-77 CCD cam-
era. The data were captured using MCID M5+ system
with a Matrox Genesis imaging board and saved in the
software format (*IM) for analysis and in *.TIF format
for reproduction. Film density was converted to local
tissue 14C concentration (nCi ⁄ g tissue) based upon the
internal standards, and the local molar concentration
(mM) were based upon the injected BCNU specific
activity of 28.9 lCi ⁄mmol. Tumor and section volumes
were determined with the same system.
Histopathological evaluation of brain tissue sections
Following autoradiography, selected slides representa-
tive of the site of injection of DTI-015 into the tumors
and into the brains of normal animals were stained
with hematoxylin and eosin and submitted to Dr.
Mark T. Butt (Pathology Associates International,
Frederick, MD) for independent histopathological
evaluation.
Radioactivity determinations in peripheral blood, tumor
samples and tissue samples
At the time of sacrifice of each animal the repre-
sentative tissues were harvested as indicated above
and stored at )70 C. Portions of these frozen sam-
ples (approximately 50 mg for blood and 100 mg for
tissues) were accurately weighed and digested in
0.5 ml of ‘Solvable’ (NEF910, NEN Research Prod-
ucts, Boston, MA) at room temperature for 48 h.
The tissue digests were decolorized with 0.25 ml of
30% H2O2 (Sigma Chemicals, St. Louis, MO), 12 ml
of Cytoscint ES (ICN Biochemicals, Costa Mesa,
CA) were added, and the samples were counted for
1 min. No quenching was observed in non-radioactive
tissue samples spiked with a known amount of
radioactivity and subjected to the same procedures.
For each series of samples a background count was
obtained for 10 blank samples counted simulta-
neously which was then averaged and subtracted
from each sample’s count.
Human blood BCNU analysis
Three patients enrolled in an IRB approved prospective
trial of DTI-015 for recurrent high-grade glioma were
treated at Evanston Hospital (Evanston, IL, 2 patients)
or The University of Southern California Medical
Center (Los Angeles, CA, 1 patient) between 11 ⁄ 13 ⁄ 01
and 7 ⁄ 12 ⁄ 02. Patients were treated per the protocol
previously described (20). Seven serial blood samples
were collected between 5 and 360 min following injec-
tion of DTI-015. Although the exact timing of each
phlebotomy was dependent upon the unique clinical
characteristics of the case each patient did have blood
draws that spanned at least a 120 min time period. For
the first two patients blood samples were immediately
extracted with ethyl-acetate and then frozen before
analysis. In the third patient blood samples were first
frozen and then extracted with ethyl-acetate at the
analytic laboratory.
Statistical and pharmacokinetic calculations
Data for radioactivity in tissues was expressed as the
mean ± standard error of the mean (SEM ¼ standard
deviation ⁄ square-root (n)1)). The SEM for ratios was
calculated using the following formula:
SEM A/B ¼ ðSEM A/mean AÞ
þ ðSEM B/mean BÞ
All statistical comparisons between groups were done
using Microsoft Excel with the Student’s t-test (two-
tailed with unequal variance) except in the comparison
between counts in tumor following direct IT injection or
IV where a single-tailed probability function was utilized
given the hypothesis that IT injection would result in
increased delivery of drug to tumors. Pharmacokinetic
calculations were performed using ‘PK Functions for
Microsoft Excel’, a series of Add-in functions for Excel
spreadsheets, designed and written by Joel I. Usansky,
Atul Desai, and Diane Tang-Liu, Department of Phar-




Injection of DTI-015 intratumorally results in increased
exposure of tumor to BCNU as compared to all other
tissues
In order to assess the pharmacokinetics of
bis-[2-chlorethyl-2-14C]-nitrosourea intra-cerebral 9L
tumors were established in Fischer 344 rats. Tumor
growth was followed by serial MRI scans (Figure 1)
where approximately 12–14 days after implantation T1-
weighted MRI pre-contrast injection revealed a large,
isointense mass in the right cerebral hemisphere with
mild compressive effect upon surrounding cerebral tis-
sues. Following IP injection of GdDTPA the tumors
were briskly and uniformly enhancing consistent with
their high-grade pathology. Once tumors had reached a
mean volume of 65 ll the rats were sterotactically in-
jected with 15 ll of 14C-labeled BCNU with injection
guided by coordinates obtained from MRI scans per-
formed the day prior to injection to assure that it oc-
curred at the appropriate location and depth within the
central mass of the tumor. Groups of 5 animals were
sacrificed 1, 15, 60, 360, 1440, and 4320 min after
injection (except for the 360 min time point which only
contained 3 animals), and radioactivity was counted in
each tissue and expressed as counts per minute per mg
of tissue (CPM/mg tissue). BCNU exerts its biologic
effect through both carbamoylation (a short-lived and
reversible phenomenon) and alkylation (a long-lived
and irreversible phenomenon) [25]. Due to the presence
of the radiolabel in both alkyl groups of bis-[2-chlor-
ethyl-2-14C]-nitrosourea, carbamylation and alkylation
are indistinguishable in this study, and no attempt was
made to quantify either these two or other products of
BCNU.
As can be seen in Figure 2a there was a rapid rise in
14C label detected in all tissues reaching a peak (Cmax)
in 15 min or less except for the blood and kidneys which
did not achieve Cmax until the 1 h time point. Not
surprisingly the time to Cmax was shorter in intra-
cerebral tissues (which were adjacent to the direct
injection of 14C-BCNU) where Cmax was typically seen
at the 1 min post-injection time point as opposed to
systemic tissues where this peak was usually at either 15
or 60 min. In all cases, following the initial peak
radioactivity there was an initial shorter half-life (t1/2)
over the first 3 h (Figure 2a) followed by a longer ter-
minal half-life from 24 to 72 h (Figure 2b and Table 1).
The half-life during the initial phase (up to 3 h after
injection) was much greater in systemic tissues (except
for kidney and lung) with an average of 12.6 ± 6.9 h
when compared to tumor and brain tissues, which had
half-lives between 1.8 and 2.4 h. This difference in initial
t1/2 is consistent with the rapid redistribution of BCNU
and metabolites from within the intra cerebral com-
partment to other systemic tissues during the early
period after injection. The shorter half-life of radioac-
tivity within the kidney likely reflects the well-docu-
mented renal excretion of BCNU and its metabolites;
while the short half-life in the lung may reflect the fact
that up to 10% of the alkyl portion of BCNU is expired
as CO2 within the first 24 h after treatment [26].
The initial fast fall in radioactivity observed during
the first 3 h was followed by a more prolonged clearance
in the period from 24 to 72 hours (Figure 2b and Ta-
ble 1) with a half-life in the tumor of greater than 72 h
and that in all other tissues markedly shorter
(41 ± 6.9 h). The main exception to this was the blood
where the terminal half-life of 68 h was much closer to
that seen for the tumor and may reflect the late slow
release of 14C-BCNU and metabolites from the tumor
into the systemic circulation.
In addition to a prolonged half-life for 14C-label, it is
also clear from this first set of experiments that 14C-
exposure to the tumor is much greater than that observed
for all other tissues both in terms of maximum concen-
tration achieved (Cmax, P < 0.0005) and in terms of net
exposure over the 72 h experiment, as expressed as the
area under the concentration vs. time curve (AUC,
P < 0.014) (Table 1). In fact, themaximal concentration
achieved in the tumor as compared to all other non-
cerebral tissues ranged between 100- and 2000- fold
higher giving a very high tumor-to-tissue ratio for Cmax
(TTR Cmax). In comparison, the ipsilateral brain was
exposed to amaximal concentration of 14C-labled BCNU
which although significantly higher than most other tis-
sues (Cmax 176.0 vs. 14.1 CPM ⁄mg tissue) was still 40-
Figure 1. Intra-cerebral 9L gliosarcoma model. T1-weight MRI images were obtained of tumor bearing animals both pre- (a) and 20 min post-IP
administration of GdDTPA (b).
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fold less than the tumor. Further, by 60 min following
injection the concentration in the ipsilateral brain
was similar to other systemic tissues (C60min 14.8 vs.
13.3 CPM ⁄mg tissue). The contralateral brain achieved
a peak concentration (37.6 CPM ⁄mg tissue) which was
between that of most systemic tissues and the ispilateral
brain, but was still ~150-fold less than that seen in the
tumor. In addition, similar to that seen for the ipsilateral
brain, by 60 min after injection there was a significant fall
in the concentration of 14C-label in the contralateral
brain such that it was similar to that for most systemic
tissues (5.24 CPM ⁄mg tissue) with only the kidneys and
liver having higher activity at this time point.
Since BCNU exerts its activity by covalent modifi-
cation of targets within the cell, peak concentrations of
14C-label may not be the best indicator of ultimate
efficacy; rather, the total exposure to 14C-BCNU and
its metabolites to the tissues of interest, as expressed as
the area under the concentration vs. time curve (AUC,
Table 1), may be a better PK parameter to monitor.
The AUC of tumor, 1912 (CPM ⁄mg tissue ⁄min · 10)3)
was 50–500 times greater than the AUC for all other
tissues yielding a very high tumor-to-tissue ratio for
AUC (TTR AUC). The kidneys, liver, and ipsilateral
brain all had similar AUCs between 17 and 40
(CPM ⁄mg tissue ⁄min · 10)3) which were 50–100-fold
less than the tumor. In contrast, the contralateral
cerebral hemisphere was exposed to an AUC for 14C-
label which was similar in nature to other systemic
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Figure 2. Time dependent distribution of radioactivity following IT delivery of 14C-labeled DTI-015 in the 9L intra-cerebral gliosarcoma model.
Fischer 344 rats bearing 9L gliosarcomas were treated with a 15 ll injection of 1,3-bis(2-chlorethyl-[2-14C])-1-nitrosourea (1 mg cold BCNU,
1 lCi 14C-label). Tumor, ipsilateral brain, contralateral brain, kidney, and blood levels are plotted individually. In addition, the average of all
other non-cerebral tissues are also depicted. Data are plotted as radioactivity (CPM/mg tissue) as a function of time (min) since injection. Values
represent the mean  SEM for 5 animals (except for the 360 min time point which only had 3 animals). Background for this experiment was
32.6 CPM. Note the different logarithmic scales on the y-axis. (a) Early data from the time of treatment to 360 minute after treatment. (b) Late
data from 360 min after treatment to 4320 min (72 h) after treatment.
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between 3.4 and 7.5 (CPM ⁄mg tissue ⁄min · 10)3) and
TTR AUC’s between 250 and 500.
Finally, not only were the Cmax and AUC increased
in tumor following injection these values may actually
have underestimated the magnitude of the therapeutic
ratio, for at the end of the 72 h experiment (Figure 2b)
there was still a significant amount of radioactivity in
the tumor (131 ± 71 CPM ⁄mg tissue). At this late
time point, in contrast, there was only minimal residual
radioactivity in all other tissues including: periph-
eral tissues (average for all extra cerebral tissues of
0.89 ± 0.18 CPM/mg tissue) and ipsilateral (1.52 ±
2.0 CPM/mg tissue) or contralateral brain (0.24 ±
0.15 CPM/mg tissue).
Intratumoral injection of DTI-015 results in improved
tumor to normal tissue ratio when compared to IV
injection of BCNU
The initial PK experiments detailed above revealed an
enhanced TTR for 14C-labeled BCNU and its
metabolites both in terms of Cmax and AUC fol-
lowing intratumoral injection of DTI-015. In order to
compare these results to that obtained following the
standard IV infusion of BCNU, PK evaluations of
14C-BCNU were performed both 6 and 72 h following
either direct intratumoral injection of DTI-015 or IV
infusion of BCNU (Figure 3a and b). Similar to the
results seen in the first experiment IT injection of
DTI-015 resulted in increased concentrations of
radioactivity in the tumor when compared to all other
tissues both within and outside the brain at both the 6
(Figure 3a) and 72-h time points (Figure 3b). Intra-
venous infusion of BCNU, on the other hand, resulted
in uniform radioactivity in tumor and non-tumor tis-
sues at both time points (Figures 3a and b). This
difference in delivery of 14C-label to the tumor fol-
lowing IT injection of DTI-015 resulted in a >100-
fold higher concentration of label within the tumor
than that achieved following IV injection of the same
quantity of drug at the 6 (P ¼ 0.065) and 72-h
(P < 0.015) time points. More importantly, although
IT injection of 14C-BCNU did afford an enhanced
exposure of tumor to the infused radioactivity it did
not significantly alter the exposure of all other tissues
when compared to IV injection at both the 6 or 72 h
time points (P > 0.5).
The enhancement in exposure of tumors to
14C-label as compared to other tissues following IT
injection when compared to IV infusion is further seen
when the tumor-to-tissue ratios (TTR) at both 6 and
72 h after administration of drug are examined
(P < 0.01). The increased concentration of 14C-label
within the tumor without a corresponding increase in
systemic exposure led to TTRs following IT injection of
DTI-015 that were all greater than 10-fold with an
average TTR of 175 ± 49 at 6-h and 97  23 at 72-h.
Not surprisingly, after IV infusion of BCNU there was
no enhancement of delivery to the tumor compared to
any other tissues with an average TTR at 6 h of
1.0 ± 0.2 and at 72 h of 0.66 ± 0.14. So, there was no
beneficial therapeutic ratio obtained following IV infu-
sion compared to a 100-fold therapeutic ratio obtained
following IT injection of BCNU.
In addition, the enhanced delivery of 14C-BCNU to
tumor is also seen when looking at the residual
radioactivity evident in the tissues of interest 72-h
after treatment. As was seen for the initial IT exper-
iments, there was significant residual radioactivity in
tumors at 72 h following IT injection
(77.1 ± 51.4 CPM ⁄mg tissue) while after IV injection
there was minimal residual radioactivity in tumor
tissue (0.89 ± 0.25 CPM/mg tissue). Despite the in-
crease in tumor radioactivity at the 72 h time point
following IT treatment there was only minimal
radioactivity in all other tissues (1.4 ±
0.5 CPM ⁄mg tissue) which was lower than that seen
for IV treatment (2.3 ± 0.9 CPM ⁄mg tissue) although
this trend approached but did not achieve statistical
significance (P ¼ 0.06).
Table 1. Pharmacokinetic parameters for DTI-015 injected intratumorally in established 9L intra-cerebral tumors in fischer 344 rats
Cmax Tumor to tissue
ratio for Cmax






Tumor 6670.0 (1347) 1912 (516) 1.8 77.7
Ipsilateral brain 176.0 (146) 38 (13.2) 28.3 (4.0) 67.6 (0.41) 2.0 50.2
Contralateral brain 37.6 (18) 178 (12.9) 5.5 (1.1) 347 (0.47) 2.4 32.0
Kidney 65.9 (16) 101 (12.6) 37.4 (6.3) 51.2 (0.44) 3.8 31.5
Liver 11.6 (1.8) 575 (12.5) 17.9 (3.5) 107 (0.47) 12.3 28.4
Lung 6.8 (2.2) 982 (12.7) 7.5 (1.4) 254 (0.45) 5.1 46.3
Spleen 3.7 (1.2) 1813 (12.7) 5.8 (0.8) 332 (0.40) 27.0 28.2
Blood 3.4 (0.54) 1944 (12.5) 6.2 (1.1) 308 (0.45) 14.9 68.0
Testes 2.7 (1.0) 2470 (12.8) 3.4 (0.5) 568 (0.41) 12.6 43.0
Pharmacokinetic parameters for 14C-labeled BCNU following IT injection of BCNU (1 mg, 1 lCi). Peak concentration (Cmax) (CPM/mg
tissue), Tumor-to-tissue ratio for Cmax (TTR Cmax), area under the curve (AUC) (CPM/mg tissue/min), and tumor-to-tissue ratio for AUC
(TTR AUC) were all calculated. In addition, the half-life of the 14C label in tissues either immediately following injection (t1/2 0-3 h) or of the late
elimination (t1/2 24–72 h) were calculated. Values in each category represent the average of 5 animals ( ± the standard error of the mean).
Background for this experiment was 32.6 CPM.
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Intratumoral injection of DTI-015 results in an enhanced
local volume of distribution compared to injection into
normal brain parenchyma
In order to more carefully evaluate both the intra-tu-
moral and intra-cerebral distribution of BCNU follow-
ing injection of DTI-015, 14C-labeled BCNU in 15 ll
ethanol was injected either into established intra-cere-
bral tumors (4 animals) or into the normal cerebral
hemisphere of non-tumor bearing animals (4 animals)
which were then sacrificed 1 or 6 h following injection
and whole brains with or without tumor were mounted
for sectioning. Representative images of these sections at
the 1 h time point are depicted in Figure 4a. One hour
after direct IT injection of 14C-BCNU into normal brain
there is a very small volume of distribution of the high
radioactive signal of 1.5 ± 0.07 ll (mean ± range) and
a relatively high concentration of BCNU within this
volume, 10.6 ± 2.1 mM (mean ± SEM) (Figure 4b).
Of note, this volume is actually smaller than the 15 ll
volume injected suggesting rapid clearance of the 14C-
BCNU from the site of injection within the first 1 h after
injection.
Pathologically at the sight of injection there was a
central zone of necrosis surrounded by a peripheral zone
of cell degeneration and a small outer zone with pallor
consistent with reactive edema. On the fusion images it
is apparent that areas of morphology consistent with
necrosis or degeneration were limited to the small vol-
ume of high radioactive signal. The radioactive signal
was largely confined to the site of injection, but in iso-
lated cases there was minimal tracking of the radioactive
signal along white matter tracts (i.e. corpus callosum or
external capsule) in which case a rim of necrosis or
edema was often associated with this tract. In addition,
if signal appeared to enter the lateral ventricle there was
some associated necrosis of ependymal cells. However,
as can be seen in the autoradiographs despite this lim-
ited tracking of 14C-BCNU into adjacent tissues the
local volume of distribution was still very small.
In contrast to what was observed in non-tumor
bearing normal brain, in the tumor bearing animals
there was a large neoplastic mass occupying the prom-
inent portion of one hemisphere (Figure 4a). The aver-
age tumor volume for all animals in this experiment was
consistent with that from our previous kinetics experi-
ments (65 ± 7.5 ll). Unlike injection of DTI-015 into
normal brain, where there was very limited distribution
of signal, following direct IT injection of DTI-015 into


























































































































Figure 3. Tissue levels of radioactivity at 6 and 72 h following administration of 14C-labeled DTI-015 IT or BCNU IV. Fischer 344 rats bearing 9L
gliosarcomas were treated with 1,3-bis(2-chlorethyl-[2-14C])-1-nitrosourea via IT injection of DTI-015 (15 ll 100%EtOH, 1 mg cold BCNU, 1 lCi
14C-label) or IV infusion of BCNU (900 ll 90% saline ⁄ 10%EtOH, 1 mg cold BCNU, 1 lCi 14C-label). At 6 and 72 h post-treatment animals were
sacrificed and radioactivity was determined in tissues. Data graphed are the mean for 5–6 animals  SEM. Background for this experiment was
19 CPM. (a) Radioactivity at 6 h for DTI-015 IT (black bars) and BCNU IV (gray bars) and (b) Radioactivity at 72 h for the same groups.
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high radioactive signal 61.1 ± 3.2 ll (mean ± range)
and a higher concentration of BCNU within this region,
40.9 ± 5.3 mM (mean ± SEM) (Figure 4a and b).
This represents a 38-fold increase in the local volume of
distribution and a 3.8-fold increase in the concentration
of BCNU delivered to this volume.
Pathologically, the high signal areas within the 9L
tumor were associated with regions of significant cellular
necrosis. There was minimal tracking of high radioactive
signal outside of the tumor volume, but in some animals
(as in the non-tumor bearing specimens) radiolabel did
enter the lateral ventricle with associated necrosis of
ependymal cells. In addition, as seen in the overlaid
images the high-signal volume for 14C-labeled BCNU
following intratumoral injection of DTI-015 closely
approximated the volume of tumor (even into areas of
the tumor which were not completely spherical but had
a more invasive component) providing evidence for en-
hanced delivery of drug not only in the small volume
where the drug was initially injected but also throughout
the mass of the tumor. In fact, the high concentration
volume of radioactive signal at one hour represented
93.9 ± 4.9% of the total tumor volume.
A similar trend in terms of enhanced local volume of
distribution and increased concentration of BCNU
delivered was noted when identical evaluations were
performed at 6 h after injection of DTI-015 into tumor
or normal brain (data not shown), but the magnitude of
the difference was smaller at this later time point con-
sistent with the clearance of BCNU from tissues during
the first 6 h (as documented in Figure 2 and Table 1).
Injection of DTI-015 or ethanol in to established 9L
tumors results in a decrease in tumor blood flow
The PK and autoradiographic data presented above
suggested a substantial difference between the delivery of
14C-BCNU to tumor and both adjacent and contralateral
brain. In an attempt to explain this phenomena, the im-
pact of intratumoral injection of DTI-105, ethanol, or
sham injection on tumor perfusion was evaluated using
MRI-based techniques. In the first set of experi-
ments animals were administered gadolinium DTPA
(GdDTPA) contrast intraperitoneally and then imaged
20, 80 and 110 min following injection of contrast. These
scans (Figure 5a) revealed abrisk rise inGdDTPAuptake
within the tumor which is highest at the 20-min time point
with a much smaller signal at 80 min and only trace
contrast enhancement at 110 min after administration of
contrast. If the same animal is treatedby sham insertion of
needle into the tumor 20 min after the administration
of contrast there is no significant change in the level or
dynamics of contrast enhancement (data not shown).
However, in animals treated with contrast followed by IT
ethanol (Figure 5b) or DTI-015 (Figure 5c) there was
increased contrast enhancement identified at both the 80
and 110-min scan. In addition, not only were there areas
of increased enhancement there were also other areas
within the ethanol or DTI-015 injected tumors with sig-
nificantly decreased contrast enhancement (which appear
as black voids on the images in 5b and 5c) perhaps do to
the inability ofGdDTPA to enter into regional volumes of
the tumor where high concentrations of ethanol were
Figure 4. Distribution of radioactive signal following treatment with 14C labeled BCNU into normal rat brain or intra-cerebral 9L tumor. (a)
Left column: Hemotoxylin and eosin stained sections of normal brain (top panel) or 9L tumors (bottom panel) 1 h post-IT injection of 14C-
[carbonyl]-1,3-bischlorethyl-1-nitrosourea (15 ll, 1 mg cold, 0.135 lCi) in 100% ethanol. Middle column: Quantitative autoradiographs of the
same tissue sections. Right column: Fusion of H&E and autoradiographic images. (b) A bar plot of the local volume of distribution in ll
(average ± range) and concentration of BCNU in mM (average ± SEM) at 1 h after injection of DTI-015 into 9L tumors (black bars) or
normal brain (white bars).
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present. In addition, when the reverse experiment was
performed where DTI-015 or ethanol were administered
20 min prior to contrast there was a corresponding de-
crease in contrast uptakewithin the tumor as compared to
animals only treated with sham insertion of the needle
into the tumor again suggesting that DTI-015 or ethanol
treatment decreased tumor perfusion as demonstrated by
alterations in dynamic contrast enhancement (data not
shown).
To further evaluate this alteration in tumor perfusion,
quantitative perfusion imaging [33] was used in intra-
cerebral 9L tumors prior to and both 1 and 24 h after:
sham, ethanol, or DTI-015 injection IT (Figure 5d).
Prior to treatment the tumors from the 3 different
groups had similar baseline blood flow (average
45.4 ± 5.6 ml/100 g/min, P < 0.91). Sham treatment
caused no significant change in blood flow at either the 1
or 24-h time points (99.2 ± 6.6% and 112.2 ± 9.3%).
In contrast, in tumors treated with IT injection of DTI-
015 there was a significant decrease in tumor perfusion
at the one hour post injection time point (57.7 ± 6.0%,
P ¼ 0.018) which had largely normalized at the 24 h and
later time points (97.6 ± 10.0%, P ¼ 0.39). In ethanol
treated animals there was a trend toward decreased
blood flow at one hour (64.6 ± 47.9%) that did not
achieve statistical significance (P ¼ 0.88). Therefore,
alterations in tumor perfusion following injection of
DTI-015 confirm the results seen in dynamic contrast
images that DTI-015 administered IT caused a transient
local decrease in tumor blood flow.
Systemic pharmacokinetics of BCNU in patients treated
with DTI-015
The rat PK data suggested both an increase in
14C-BCNU delivery to tumor and a markedly enhanced
TTR ratio for 14C-BCNU administered by IT injection
as compared to IV infusion. In order to perform an
initial evaluation of systemic exposure to BCNU fol-
lowing treatment with DTI-015 three patients treated on
a prospective clinical protocol for recurrent high-grade
glioma (20) had blood levels of BCNU determined at
serial time points after injection of DTI-015. Following
treatment with DTI-015 the Cmax in the blood
(93.6 ± 49.3 ng/ml) was observed approximately 1 h
following injection (53 ± 14 min, Figures 6a and b).
This peak blood concentration of BCNU occurred both
later and was lower than that previously observed fol-
lowing IV administration of BCNU to patients where a
peak concentration of 2000 ng/ml was observed at
40 min following the start of a 30-min IV infusion (i.e.
10 min after the completion of treatment) [27]. This
enhanced therapeutic index is further highlighted by the
fact that for patients being treated with DTI-015 the
average injected mass of BCNU (3.98 ± 0.76
mg/kg) was 2-fold higher than that utilized for IV
infusion (1.71 ± 0.11 mg/kg). Finally, despite the al-
tered route of administration the terminal clearance of
BCNU from the systemic circulation was similar in both
cases with the half-life observed for all time points >45
min of 106 ± 14 min for DTI-015 administration and
95 min for IV treatment.
Discussion
The experiments reported here reveal both the local and
systemic distribution of 14C-label following IT delivery
of 14C-BCNU in the rat 9L gliosarcoma model. As
indicated there was a >100-fold increase in the
amount of radioactivity delivered to tumor tissue
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Figure 5. Dynamic contrast imaging and tumor blood flow following Ethanol or DTI-015 treatment of 9L tumors. T1-weighted MR images of
9L tumors either before (pre-) or 20, 80, or 110 min following IP administration of GdDTPA. Treatment was performed after the 20 min scan
and consisted of no treatment (control, a), or injection of 15 ll ethanol (b), or DTI-015 (c). In Figure 6d, quantitative perfusion imaging of 9L
tumors was performed before and both 1 and 24 h after the same three treatments. Blood flow in tumors as a percentage of baseline blood flow is
plotted for the average ± SEM of 3 animals for: Sham (black bars), ethanol (gray bars), or DTI-015 (white bars).
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following DTI-015; in addition, despite the increased
delivery of drug to tumor via IT injection there was no
appreciable increase in the systemic exposure to 14C-
BCNU or its metabolites compared to IV treatment.
The dose of 1 mg of BCNU utilized by either route in
this study corresponds to 6.6–8.0 mg/kg which is similar
to the 12 LD10 dose previously reported (6.65 mg/kg),
where LD10 equals the dose that caused death due to
drug toxicity in 10% of the animals [28]. In previous
reports, treatment with the 12 LD10 dose systemically
caused a small cytotoxic effect in this 9L gliosarcoma
model (0.2 log cell-kill), a modest change in apparent
cellular water diffusion, no appreciable increase in ani-
mal survival, and no systemic toxicity [28,29]. Therefore,
these kinetic data suggest that the in the 9L intracerebral
rat model the use of DTI-015 at the dose of 1 mg pro-
vides at least a 100-fold increase in tumor exposure to
BCNU compared to IV administration while providing
a systemic exposure that has been documented to be well
tolerated with minimal toxicity.
In addition, the enhanced delivery of 14C-BCNU to
tumor compared to systemic tissues following treatment
with DTI-015 is similar to what was previously observed
by measuring DNA adducts in RIF-1 flank tumors
grown in nude mice following either IP infusion of
BCNU or IT injection of DTI-015 where there was a
164-fold increase in the DNA adducts identified in the
tumor after treatment with DTI-015 as compared to IP
infusion. In addition, despite the increased delivery of
BCNU to flank tumors, the level of adducts in other
systemic tissues (brain, lung, liver, and kidney) were not
increased above background following IT treatment
with DTI-015 [30].
The enhancement in the tumor exposure to 14C-
BCNU and its metabolites following injection of DTI-
015 likely explains the therapeutic advantage previously
reported for rats bearing 9L gliosarcoma treated with
DTI-015 [23]. In that study rats received a volume of
DTI-015 up to 50% of the tumor volume or 30 ll,
whichever was smaller, containing up to 2 mg of
BCNU. This treatment regimen was based on that pre-
viously reported in the phase I ⁄ II trial of DTI-015 in
patients with recurrent high-grade glioma [20]. That
study escalated the volume of ethanol and the dose of
BCNU utilized in parallel to achieve the maximum
values for these two parameters. The MTD was even-
tually established as 50% of the tumor volume up to
5 ml and 240 mg BCNU. Therefore, when performing
studies to evaluate MRI based measures of early ther-
apeutic efficacy [23] similar parameters were utilized for
the rat glioma model.
Treatment with these parameters in the 9L glioma
model resulted in massive cell death (as documented by
diffusion weighted MRI), complete radiographic
regression of tumor by 16 days post injection, and 75%
of animals tumor free at 30 days after treatment. This is
significantly better than that previously observed using
systemic administration of a much higher dose of
BCNU (2 · LD10 BCNU or 3.3–4.0 mg) where only
minimal tumor regression with no complete responses
was observed and all animals still succumbed to tumor
related death within 20 days of treatment [22,29]. Taken
together these sets of data suggest that IT injection of
DTI-015 results in a dramatic increase in tumor re-
sponse to treatment compared to systemic infusion even
for a smaller dose of drug delivered IT. Further, the
current PK data which reveal a greater than 100-fold
increase in delivery of 14C-BCNU to tumors by IT
treatment compared to IV infusion represent a viable
explanation of the enhanced efficacy observed in this
preclinical model of high-grade glioma.
Clinically diffuse fibrillary high-grade gliomas are
known for the invasive nature of the disease with tumor
cells often found on pathologic review as much as many
centimeters from the site of the tumor within what
grossly appears to be normal brain tissue [1]. It is un-
clear how the result obtained using the 9L gliosarcoma
model, where intracerebral tumors tend to grow as a
contained mass with little invasion in to the surrounding
brain tissue, can be extrapolated to invasive nature of
primary high-grade brain tumors. To date, a preclinical
model of DTI-015 in an infiltrative tumor model has not
yet been reported to ascertain whether or not adminis-
tration of DTI-015 will result in enhanced delivery of
BCNU to infiltrating tumor cells. However, the local
distribution of 14C-BCNU in tumors observed in the
present study following direct IT injection of DTI-015
would suggest transit of drug throughout the tumor. In
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Figure 6. Systemic pharmacokinetics of BCNU in humans following
IV infusion of BCNU or IT delivery of DTI-015. (a) The concentration
of BCNU in peripheral blood (ng ⁄ ml) as a function of time after start
of infusion (minutes) is plotted for 3 patients treated with DTI-015
(open square, open triangle, and closed diamond) or for the average of
4 patients treated by IV infusion (x-symbols). Data for IT represent the
actual values at each time point and that for IV the mean ± SEM
taken from Cancer Treat Rep, 62: 1305–1312, (1978). (b) Peak con-
centration of BCNU in serum for the above patients.
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appeared to have significant tracking of radioactive
BCNU suggesting that following injection of DTI-015
the drug was not simply expanding to fill a spherical
volume, but it was in fact being transported preferen-
tially in tumor tissue as compared to surrounding nor-
mal brain. Indeed approximately 90% of the tumor
appeared to harbor the highest signal intensity of
BCNU which correlated with a concentration of 40.9 ±
5.2 mM. This is much higher (>300-fold) than the IC95
(100 lM) observed in culture for BCNU in the 9L cells
used in this study (D.A.H., unpublished data).
The local PK data in this animal model also confirm
the previous report of a patient with recurrent GBM
treated with DTI-015 (240 mg in 4 ml) where 60 min
after treatment stereotactic biopsies were performed and
measurement of DNA adducts revealed an 879-fold in-
crease above background in tumor tissue up to 0.9 cm
from the site of injection and a 6-fold increase above
background for tissue even up to 2.4 cm from injection
[31]. The combination of enhanced local concentrations
of drug and increased delivery of drug to surrounding
brain may explain the quite positive result observed in
the phase I ⁄ II trial where patients with recurrent inop-
erable GBM still achieved a median survival of
55 weeks, which is comparable to that for most patients
at the time of diagnosis, and was considerably better
than matched historical controls at the same treating
institution where the median survival of recurrent and
unresectable patients was only 25 weeks [20].
Therefore, both preclinical and clinical data suggest
that solvent facilitated perfusion enhances delivery of
BCNU to tumors following IT injection. However, the
mechanism by which ethanol facilitates the transit of
BCNU throughout the tumor has not been fully eluci-
dated. It does appear to be a factor of the organic sol-
vent, for treatment of Walker 256 flank tumors with
direct injection of BCNU in either 100% ethanol or
10% ethanol/90% saline gave markedly different anti-
tumor response even for the same dose of BCNU [32].
A number of hypotheses can be made as to the mecha-
nism of the preferential delivery of 14C-BCNU to the
tumor following IT treatment with DTI-015.
First, 9L tumors have been documented to have a
higher cellular density and choline : ethanoloamine ratio
than surrounding normal rat brain suggesting a more
lipophilic cellular mass [33]. Ethanol may, therefore,
facilitate partitioning of BCNU into this lipophilic tumor
better than BCNU in water, and this enhanced parti-
tioning may be greater in tumor than in normal brain
which is not as lipophilic. Transit of BCNUmay, thus, be
facilitated in this fashion within the tumor until the sol-
vent interface reaches normal brain tissue at which time
there is less of an advantage for the organic solvent and
decreased movement of the drug into surrounding brain
parenchyma.
A second possible contributing factor is the docu-
mented fact that 9L tumors have lower blood flow than
normal surrounding brain [34,35] which by our mea-
surements was 45.4 (ml ⁄ 100 mg tissue ⁄min) in tumor
vs. 138 ± 25 (ml ⁄mg tissue ⁄min) in the brain sur-
rounding the tumor [36]. As a result of this decreased
blood flow within the tumor the injected BCNU would
have lower clearance in tumor as compared to normal
surrounding brain allowing a greater chance for the
drug to diffuse throughout the tumor. Similarly, once
the drug does diffuse out of the tumor into normal
brain tissue the greater perfusion of these tissues would
result in enhanced clearance, and, therefore, lower
residual concentrations of BCNU in brain tissue.
A third option, which is in part supported by our
perfusion and dynamic contrast images, is that either
BCNU, ethanol, or the combination may alter the
blood flow within the tumor thus further enhancing the
retention of the drug within the tumor as compared to
surrounding tissues. One possible mechanism to explain
these different responses in perfusion to DTI-015
treatment is that the aberrant blood vessels which de-
velop within the tumor via neoangiogenic processes may
be more susceptible to this alteration in blood flow
following injection of DTI-015 than mature vessels
found within the surrounding brain parenchyma. Fi-
nally, it is also may be that each of these three theories
and perhaps other undetermined factors all contribute
to both the increased local volume of delivery of BCNU
to tumors and the enhanced TTR observed following
administration of DTI-015.
Finally, preliminary data are presented on the sys-
temic exposure of patients to BCNU following IT
injection of DTI-015 and are compared to previously
published results for IV infusion of BCNU. Despite a
2-fold increase in the amount of administered BCNU,
in the patients tested DTI-015 resulted in a 20-fold
decrease in the Cmax for BCNU in the peripheral
blood. Despite this decreased Cmax there was no
apparent difference in the clearance of BCNU from the
systemic circulation as determined by the terminal half-
life. It is interesting to note that the human data re-
vealed a 20-fold decrease in the systemic BCNU
exposure between these two modes of administration
while the rat PK data reported similar overall systemic
exposure. One potential explanation for this difference
is that the human clinical data measured absolute
BCNU levels, while the rat PK data recorded 14C
radioactivity. Therefore, much of the late radioactivity
seen in the rat model my represent inactive metabolites
or terminal adducts of BCNU and not the native
compound.
Conclusion
The use of DTI-015 offers a 100-fold or greater in-
crease in the delivery of 14C label to intra-cerebral 9L
tumor compared to IV administration without any
increase in the systemic exposure. Further, injection of
14C-BCNU in ethanol appears to provide rapid and
near complete saturation of tumors by BCNU with
little deposition of drug into surrounding tissues,
which may be in part due to alterations in tumor
blood flow following injection of DTI-015. Finally, in
patients treated with DTI-015 as compared to IV
infusion of BNCU there is: a delay in the time to
achieve Cmax, a decrease in systemic exposure to
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BCNU, but a similar terminal elimination rate for
BCNU. All of these preclinical and clinical data sug-
gest that DTI-015 warrants further investigation as a
means to provide enhanced tumor specific delivery of
BCNU to patients with high-grade glioma.
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